Agency
County of Harnett Dba Harnett County Health Department
County of Harnett Dba Harnett County Health Department was paid $4.43M by Medicaid between Jan 2018 and Dec 2024, across 90 billing codes. Its largest line is 99199, Unlisted special service, procedure or report — 53% of everything it billed.
33Billing provider infoCOUNTY OF HARNETT DBA HARNETT COUNTY HEALTH DEPARTMENT
LILLINGTON, NC 27546
LILLINGTON, NC 27546
33aNPI1215048459assigned 08/31/2006
33bProvider typeCase Management Agency
28Total paid$4.43M
24GClaims552,702
24DCodes billed90
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Case Management Agency providers in North Carolina
Rank by total paid#59 of 195
Median peer was paid$2.05M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 14,867 | $281K | |
| 2019 | 15,032 | $280K | |
| 2020 | 12,191 | $267K | |
| 2021 | 68,625 | $652K | |
| 2022 | 142,250 | $1.02M | |
| 2023 | 145,973 | $945K | |
| 2024incomplete | 153,764 | $978K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99199 | Unlisted special service, procedure or report | 53% | 446,507 | 399,185 | $2.35M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 18% | 10,491 | 8,143 | $782K |
| 90472 | Immunization administration, each additional vaccine (list separately) | 3.8% | 6,420 | 5,416 | $167K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 3.3% | 10,730 | 8,686 | $144K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 3.0% | 4,441 | 3,853 | $134K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 2.2% | 1,097 | 960 | $98K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.3% | 324 | 301 | $60K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1.2% | 609 | 503 | $52K |
| T1002 | Rn services, up to 15 minutes | 1.1% | 2,201 | 1,512 | $47K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 1.1% | 669 | 480 | $47K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | <1% | 402 | 324 | $39K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 798 | 628 | $39K |
78 more codes
| S0280 | Medical home program, comprehensive care coordination and planning, initial plan | <1% | 811 | $37K |
| 83655 | <1% | 2,472 | $36K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 3,460 | $34K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 841 | $31K |
| 96127 | <1% | 5,195 | $30K | |
| 87428 | <1% | 560 | $29K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 1,528 | $26K |
| 99502 | <1% | 399 | $23K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,386 | $20K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,489 | $20K |
| 99501 | <1% | 381 | $19K | |
| 81025 | <1% | 2,430 | $18K | |
| 99383 | <1% | 191 | $15K | |
| 90651 | <1% | 1,022 | $13K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,435 | $13K |
| 81003 | <1% | 4,877 | $13K | |
| 85027 | <1% | 1,717 | $12K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 816 | $11K |
| 90474 | <1% | 681 | $8K | |
| 90734 | <1% | 563 | $7K | |
| 90715 | <1% | 1,376 | $6K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 64 | $6K |
| 90619 | <1% | 1,772 | $5K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 38 | $5K |
| 92551 | <1% | 3,023 | $4K | |
| 87210 | <1% | 1,792 | $4K | |
| 90686 | <1% | 2,178 | $3K | |
| 90716 | <1% | 252 | $3K | |
| 90621 | <1% | 293 | $3K | |
| 96160 | <1% | 739 | $2K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 25 | $2K |
| 87807 | <1% | 151 | $2K | |
| 99173 | <1% | 3,194 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 192 | $1K |
| 90707 | <1% | 210 | $1K | |
| 90674 | <1% | 95 | $755.53 | |
| 99406 | <1% | 86 | $703.87 | |
| 96161 | <1% | 336 | $693.66 | |
| 90633 | <1% | 1,323 | $689.08 | |
| 90480 | <1% | 33 | $650.00 | |
| 90661 | <1% | 83 | $622.75 | |
| 82950 | <1% | 170 | $597.42 | |
| 83020 | <1% | 641 | $361.78 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 506 | $278.71 |
| 86580 | <1% | 49 | $249.94 | |
| 86701 | <1% | 1,099 | $121.68 | |
| 80061 | Lipid panel | <1% | 50 | $117.56 |
| 90744 | <1% | 917 | $93.32 | |
| 86593 | <1% | 1,152 | $78.94 | |
| 82105 | <1% | 282 | $43.44 | |
| 90656 | <1% | 187 | $20.53 | |
| 90681 | 0% | 598 | $0.00 | |
| 90700 | 0% | 195 | $0.00 | |
| 86900 | 0% | 319 | $0.00 | |
| 87341 | 0% | 18 | $0.00 | |
| 90670 | 0% | 2,229 | $0.00 | |
| 86787 | 0% | 406 | $0.00 | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 0% | 195 | $0.00 |
| 90685 | 0% | 121 | $0.00 | |
| 90710 | 0% | 633 | $0.00 | |
| 90756 | 0% | 137 | $0.00 | |
| 90713 | 0% | 15 | $0.00 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 18 | $0.00 |
| 90698 | 0% | 1,479 | $0.00 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 0% | 539 | $0.00 |
| 90677 | 0% | 312 | $0.00 | |
| 90696 | 0% | 197 | $0.00 | |
| 86850 | 0% | 335 | $0.00 | |
| 87800 | 0% | 615 | $0.00 | |
| 86762 | 0% | 288 | $0.00 | |
| 86706 | 0% | 269 | $0.00 | |
| 90694 | 0% | 12 | $0.00 | |
| 90697 | 0% | 167 | $0.00 | |
| 86901 | 0% | 244 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 17 | $0.00 |
| 88142 | 0% | 48 | $0.00 | |
| 86803 | 0% | 33 | $0.00 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJOHNSON, AINSLEY (HEALTH DIRECTOR)
Parent organizationHARNETT COUNTY HEALTH DEPARTMENT
| Provider | Location | Paid |
|---|---|---|
| County of Harnett | Lillington, NC | $2.38M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.